Compounds > 2-(4-hydroxyphenyl)-4,5-diphenylimidazole
Page last updated: 2024-11-08

2-(4-hydroxyphenyl)-4,5-diphenylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID352144
CHEMBL ID390388
SCHEMBL ID252964
MeSH IDM0482815

Synonyms (37)

Synonym
4-(4,5-diphenyl-1h-imidazol-2-yl)phenol
EU-0047402
nsc683642
OPREA1_873701
1752-94-9
nsc-525164
nsc525164
nsc-683642
OPREA1_149383 ,
SR-01000511510-2 ,
4-(4,5-diphenyl-2-imidazolyl)phenol, suitable for chemiluminescence, >=99.0% (hplc)
CHEMBL390388
AKOS000579005
4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)cyclohexa-2,5-dien-1-one
D4178
2-(4-hydroxyphenyl)-4,5-diphenylimidazole
4-(4,5-diphenyl-2-imidazolyl)phenol
SCHEMBL252964
JMBUODONIOAHPZ-UHFFFAOYSA-N
DTXSID50419769
ck967
4-(4,5-diphenyl-4-imidazolin-2-ylidene)cyclohexa-2,5-dien-1-one
bdbm67466
cid_5385986
4-(4,5-diphenyl-1,3-dihydroimidazol-2-ylidene)-1-cyclohexa-2,5-dienone
sr-01000511510
SR-01000511510-1
AS-65383
J-011105
mfcd00740542
4-(4,5-diphenyl-1h-imidazol-2-yl)phenol [for biochemical research]
2-(4-hydroxyphenyl)-4,5-diphenylimidazol
phenol, 4-(4,5-diphenyl-1h-imidazol-2-yl)-
BAA75294
CS-W009425
HY-W008709
Z60248806
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NADPH oxidase 1Homo sapiens (human)IC50 (µMol)17.00000.04401.26095.5000AID2808
Oligo-1,6-glucosidase IMA1Saccharomyces cerevisiae S288CIC50 (µMol)97.12009.37009.37009.3700AID1800999
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID1389179Inhibition of electric eel AChE at 10 uM using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID284328Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1389182Antioxidant activity in brain homogenate (unknown origin) assessed as decrease in TBARS formation by UV-visible spectrophotometric method2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID1335178Antimalarial activity against chloroquine-resistant asexual erythrocyte stage of Plasmodium falciparum K1 infected in human type O+ erythrocytes assessed as growth inhibition incubated for 48 hrs by NBT dye based LDH release assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID284330Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 30 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284333Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284331Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 60 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284338Antiinflammatory activity assessed as reduction of carrageenan-induced paw volume in intraperitoneally dosed Wistar rat after 3 hrs2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284332Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 120 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1389178Inhibition of equine serum BChE at 10 uM using S-butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition and measured for 45 mins by Ellmans microplate assay2018Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
AID284336Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 60 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284329Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 15 mins by hot plate method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1335175Inhibition of beta-hematin formation incubated for 5 to 6 hrs by NP40 detergent-mediated assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID284337Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 120 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284334Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 15 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID284335Antinociceptive activity in ip dosed Swiss albino mouse assessed as latency time after 30 mins by tail flick method2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Antinociceptive and antiinflammatory activities and QSAR studies on 2-substituted-4,5-diphenyl-1H-imidazoles.
AID1335177Antimalarial activity against chloroquine-sensitive asexual erythrocyte stage of Plasmodium falciparum NF54 infected in human type O+ erythrocytes assessed as growth inhibition incubated for 48 hrs by NBT dye based LDH release assay2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against
AID1800999Alpha-glucosidase Inhibition Assay from Article 10.1016/j.bioorg.2014.11.006: \\Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for a-glucosidase inhibition to treat diabetes.\\2015Bioorganic chemistry, Feb, Volume: 58Organocatalyzed solvent free an efficient novel synthesis of 2,4,5-trisubstituted imidazoles for α-glucosidase inhibition to treat diabetes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alfuzosin
alfuzosin: structure given in first source		2.1710monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol		alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.1510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
donepezil
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.		2.1710aromatic ether;
indanones;
piperidines;
racemate		EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent
dyclonine
[no description available]		2.1710aromatic ketone;
piperidines		topical anaesthetic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.0310aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
nefazodone
nefazodone: may be useful as an opiate adjunct		2.1710aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles		alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		2.1710organonitrogen compound;
organooxygen compound
physostigmine
Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.		2.1710carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		2.1710benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
lophine
[no description available]		2.7930
2-phenylimidazole
[no description available]		2.1510
acarbose
[no description available]		2.1110amino cyclitol;
glycoside
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.1710ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		02.0310
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0310
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.1110
Acute Confusional Senile Dementia
[description not available]		02.1710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.1710
Age-Related Memory Disorders
[description not available]		02.1710
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.1710
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.1710